If you look at the prescription records of any large group of people with schizophrenia, you'll find that roughly 20–30% are taking two or more antipsychotics simultaneously. Surveys show this fraction is even higher in the public mental health system and in inpatient settings. Yet every major treatment guideline — APA, NICE, RANZCP — recommends antipsychotic monotherapy as the standard, and lists polypharmacy as a strategy of last resort.
So what's going on? And when, if ever, is two genuinely better than one?
Combining two antipsychotics has limited evidence of benefit, doubles the side-effect burden, and is rarely supported by guidelines — but in a small set of specific situations (clozapine augmentation, transition periods, LAI plus oral coverage), it can be appropriate.
How polypharmacy happens
Polypharmacy is rarely a planned strategy. It usually accumulates:
- A patient on antipsychotic A is in crisis. Antipsychotic B is added for acute control. The crisis resolves but B never gets stopped.
- A patient is being switched from A to B by cross-titration. The switch never gets completed.
- A new prescriber inherits a complex regimen and is reluctant to change anything.
- A long-acting injection is in place and oral medication is added "just in case."
Once two antipsychotics are on board, removing one feels riskier than continuing both, even if the original reason for the second is gone.
Where the evidence actually supports combination
Clozapine plus a second antipsychotic for partial responders
This is the strongest evidence base. Adding aripiprazole or amisulpride to clozapine in patients who are partial responders has shown modest benefit in several controlled trials and meta-analyses. Aripiprazole augmentation also helps with clozapine-related weight gain and prolactin elevation. See clozapine augmentation strategies for the broader picture.
Long-acting injection plus oral coverage during transitions
When initiating a long-acting injection (LAI), oral medication is often continued for the first 1–4 weeks until LAI levels stabilise. This is planned, time-limited combination. Some clinicians continue low-dose oral coverage long term for breakthrough symptoms, though this is more controversial.
Acute crisis management
In severe acute psychosis, a second antipsychotic (sometimes given parenterally) may be used for short-term control. This should be a temporary measure with a clear plan for tapering one drug after the crisis resolves.
Where the evidence is weak or absent
- Two non-clozapine antipsychotics for chronic maintenance. Most controlled trials show no advantage over monotherapy for combinations like risperidone plus quetiapine or olanzapine plus aripiprazole.
- Three or more antipsychotics. Almost no evidence supports this. Side effects accumulate, drug interactions multiply, and the rational basis evaporates.
- "Targeting different symptoms" with two antipsychotics. This is a common rationale (e.g., one for positive symptoms, one for negative). It rarely holds up in trials.
The downsides of stacking
Side effect burden
Each antipsychotic carries its own side effect profile. Stacking adds them: more weight gain, more sedation, more anticholinergic effects, more EPS, more QT prolongation, more metabolic risk. These don't combine linearly — they often combine multiplicatively.
Mortality risk
Some — but not all — observational studies link antipsychotic polypharmacy with increased all-cause mortality, particularly cardiovascular mortality. The Finnish national register studies (Tiihonen et al.) suggest that specific combinations (clozapine + aripiprazole) may be safer than expected, while indiscriminate combinations may be more harmful. The picture is nuanced.
QT prolongation
Combining drugs that each prolong the QT interval (especially ziprasidone, iloperidone, IV haloperidol, and some others) raises the risk of dangerous arrhythmias. ECG monitoring is appropriate when two QT-affecting drugs are combined. See QT prolongation and antipsychotics.
Drug interactions
Antipsychotics share metabolic pathways. Adding one can raise or lower the level of another, sometimes substantially. Plasma-level monitoring is more useful when combinations are in play.
Adherence problems
More pills, more side effects, more cost. Polypharmacy reliably worsens adherence over time, which can offset whatever benefit it was supposed to provide.
It is reasonable to ask your prescriber: why both? When was the addition made and for what reason? Is the original reason still relevant? What would happen if we tapered one?
Why this conversation can be hard
For many patients, the regimen they're on now has kept them stable for years. The instinct — and often the right instinct — is "don't fix what isn't broken." Tapering an antipsychotic carries real relapse risk, even when the drug doesn't appear to be doing much. A reasonable de-prescribing plan is usually slow (months, not weeks), watchful, and coordinated with the prescriber. NICE has guidance on antipsychotic review at nice.org.uk/guidance/cg178.
The non-pharmacological add-on that should be considered first
Before adding a second medication, the better-evidenced add-on is often CBT for psychosis. It has independent benefit, no medication interactions, and is grossly underused worldwide.
The bottom line
Polypharmacy is common, often accidental, and rarely evidence-based. The exceptions — clozapine augmentation, planned transitions, brief crisis use — are real but narrow. If you're on more than one antipsychotic, the question is worth raising calmly with your prescriber, not as criticism, but as a normal part of long-term review.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.